Clinical trial NCT06102213: Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation
Official title: A Randomized, Open-Label, Multicenter, Phase 2a Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Hematologic Malignancy
Keywords: allo-hct
microbiome
gut engraftment
Lead sponsor: Prolacta Bioscience
Sponsor class: INDUSTRY
First posted: 2023-10-26
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 3 cohorts: Cohort A and B receive combination study drug in difference doses (Cohort A receives HMO 9.0 g and B. infantis; Cohort B received HMO 4.5 g and B. infantis) Cohort C does not receive study drug
Primary purpose: TREATMENT

Brief summary: This is a Phase 2a, open-label, multicenter study to evaluate the safety and efficacy of HMO (PBCLN-010) and B. infantis (PBCLN-014) on the gut microbiome and GI domination by pathobionts in participants receiving allo-HCT.

Approximately 60 participants will be enrolled in this study, and all participants will undergo screening assessments up to 28 days before the first study drug dose (D 7). Participants meeting all the eligibility criteria based on the screening assessments will be enrolled and randomly assigned to 1 of the 3 cohorts:

* Cohort A (HMO 9.0 g and B. infantis) BID
* Cohort B (HMO 4.5 g and B. infantis) BID
* Cohort C (Control Cohort): Participants in this cohort will not receive any study drug.


Eligibility criteria: Inclusion Criteria:

1. Signed informed consent prior to initiation of any study-specific procedure or treatment.
2. Male and female participants 18 to 75 years of age at the time of informed consent.
3. Planning to receive a first allo-HCT.
4. Able to comply with protocol requirements.

Exclusion Criteria:

1. Participants with prior bowel resection resulting in colostomy
2. Serious medical or psychiatric illness likely to interfere with participation in study.
3. History or presence, upon clinical evaluation, of any illness that, in the opinion of the Investigator, would interfere with the ability to provide informed consent or comply with study instructions.
4. Female participants who are pregnant, breastfeeding, lactating, or planning to become pregnant during the study.

Primary outcomes:
measure: Incidence and severity of safety and tolerability measures assessed through adverse events, serious adverse events, and adverse events of special interest per treatment group
timeFrame: before treatment, during treatment, or ≤ 56 days after cessation of treatment
measure: Rate of gut engraftment of B. infantis through Day 180 among recipients of PBCLN-010 in combination with PBCLN-014 compared with standard of care (SOC) (control cohort).
timeFrame: Through study completion,180 days
measure: Duration of gut engraftment of B. infantis through Day 180 among recipients of PBCLN-010 in combination with PBCLN-014 compared with standard of care (SOC) (control cohort).
timeFrame: Through study completion,180 days
Secondary outcomes:
measure: Measures of safety and tolerability by physical examinations examined by cohort to assess the effect of oral administration of PBCLN-010 in combination with PBCLN-014
timeFrame: Dosing period, 43 days
measure: Measuring the incidence of bloodstream infections, use of anti-infective agents, frequency/length of hospitalizations stays to evaluate the incidence of the infection and other safety events among recipients of study drug compared with SOC
timeFrame: Through study completion,180 days
measure: Measuring temperature ≥ 38.0°C (100.4°F) sustained over a 1-hour period concurrent with ANC < 500 cells/mm3 to determine the incidence and duration of febrile neutropenia
timeFrame: Day -7 through neutrophil engraftment
measure: Measuring cases of acute graft versus host disease (aGvHD) to determine the cumulative incidence or rate of acute graft versus host disease (aGvHD) at D180
timeFrame: Through study completion,180 days
Other outcomes:
Locations:
city: Houston
country: United States
facility: The University of Texas MD Anderson Cancer Center
state: Texas
Study officials:
References: